Dr. Saima Hassan, Surgical Oncologist at the CHUM in Montreal and co-author of the B-59/GeparDouze study, emphasizes Quebec's role, contributing 17% of patients. She discusses the study's findings, its implications, and the need for further biomarker exploration.
